Development of a Chimeric c-Src Kinase and HDAC Inhibitor

Development of a Chimeric c-Src Kinase and HDAC Inhibitor Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors